The Division of Therapeutics and Medical Consequences (DTMC) of NIDA supports and conducts studies to evaluate the safety and efficacy of new pharmacotherapies, biologics, behavioral therapies, devices, and digital therapeutics for Substance Use Disorders (SUDs). DTMC supports research through peer-reviewed grants and contracts for all stages of medications development including  preclinical evaluation of potential therapeutics, clinical trial design and execution, and the preparation of regulatory submissions. The Regulatory Affairs Branch provides expert regulatory guidance and consultation in support of DTMC's medications development efforts.    Regulatory Affairs:  The incumbent serves as a Health Scientist Administrator (HSA) specializing in Regulator